RxDoctor Payments Data

Wendy Sosa Guzman, OD

Optometrist · Hialeah, FLNPI 1063070803

Payments from drug & device makers

$2,759in general payments, 2019–2025

Across 97 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$927
  • AbbVie$375
  • NEW World Medical,inc.$240
  • Oyster Point Pharma, Inc.$179
  • Aerie Pharmaceuticals, Inc.$142
  • Sight Sciences, Inc.$124
  • plus $774 from 13 others

What the payments were for

  • Food & beverage$2,759100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,759 in reported general payments places this provider in the 75th percentile of 3,166 optometrist providers in Florida.

See all optometrist providers in Florida

Medicare billing

Part B allowed, 2024
$24,193
Medicare patients
94
Services billed
290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine264$207,879
LumiganBimatoprost139$38,249
CombiganBrimonidine Tartrate/Timolol138$37,975
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol292$26,896
XiidraLifitegrast26$21,873
VyzultaLatanoprostene Bunod46$16,121
RhopressaNetarsudil Mesylate38$13,933
Cyclosporine38$10,213
SimbrinzaBrinzolamide/Brimonidine Tart49$10,083
Alphagan PBrimonidine Tartrate33$8,971
IlevroNepafenac18$8,220
RocklatanNetarsudil Mesylat/Latanoprost20$8,002
Prednisolone Acetate266$7,927
LinzessLinaclotide12$5,937
Latanoprost965$5,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P, Linzess$375$299,012586 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$85$37,99472 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$142$21,93558 claims
NovartisIlevro$41$8,22018 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$46$3,10520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,166 optometrist providers in Florida.

Other optometrist in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →